Rituximab combined with a TNF inhibitor and methotrexate shows no safety signal in rheumatoid arthritis treatment, study finds

A recent trial of rituximab in combination with a tumor necrosis factor (TNF) inhibitor and methotrexate (MTX) in patients with active rheumatoid arthritis (RA) found the safety profile to be consistent with other RA trials with TNF inhibitors. While the trial reported no new safety risks, clear evidence of an efficacy advantage in RA patients receiving the combination therapy was not observed in this study sample.

Read the whole article on Science Daily

More from Science Daily